Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 AF-0901 (midazolam) open-label study in pediatric status epilepticus
jRCT2080223531Phase 3
- Sponsor
- Alfresa
- Start
- May 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of midazolam in status epilepticus (SE), sponsored by Alfresa.
02
Drugs
midazolam
03
Conditions
status epilepticus (SE)
Beyond the preview
Go deeper on jRCT2080223531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223531.